It will be intriguing to identify the optimal ways of dually targeting FcRH5 and BCMA with CAR T cells in order to achieve the potent anti-MM efficacy while diminishing the likelihood of relapse from antigen loss. This evidence concerns the gene FCRL5 and Miyoshi myopathy.